Pinealon vs Pal-AHK
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
- Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
- Half-Life
- Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
- Extended (lipid depot effect in stratum corneum)
- Admin Route
- SubQ, Oral, Intranasal
- Topical
- Research
- —
- —
- Typical Dose
- 5–10 mg (oral) or 50–100 mcg (SC)
- 0.01–0.05% in formulation
- Frequency
- Once daily for 10 days
- Once or twice daily
- Key Benefits
- Neuroprotection against oxidative stress and hypoxia
- Promotes neuronal regeneration and repair
- Improves memory and cognitive function
- Enhances sleep quality via melatonin regulation
- Anti-aging effects on brain cells
- May slow cognitive decline in neurodegeneration
- Improves cerebrovascular circulation
- Reduces neuroinflammation
- Enhanced skin penetration vs. unmodified AHK-Cu
- Stimulates dermal collagen and elastin production
- Promotes hair follicle anagen phase
- Antioxidant and wound healing activity
- Firming and plumping effect on aging skin
- Improved bioavailability via lipid bilayer incorporation
- Side Effects
- Excellent safety profile in clinical use
- Rare: mild drowsiness
- Transient mild headache at initiation
- Injection site reaction (SC)
- Generally well-tolerated
- Mild irritation at high concentrations in sensitive skin
- Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
- Stacks With
- —
- —